Harnessing Synapse for Sumatriptan Information: Strategies and Tips

Sumatriptan is a small molecule drug and developed by GSK. Its first approved in 1996 in the USA. Sumatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine and cluster headaches through agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Some scientists believe that sumatriptan may act as an agonist at the 5-HT1B/1D receptors, triggering a response and activating the receptors, which ultimately translates into a reprieve from the misery of migraine and cluster headaches. Click on the image below to begin the exploration journey of Sumatriptan through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!